Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human GAA Antibodies:
anti-Mouse (Murine) GAA Antibodies:
anti-Rat (Rattus) GAA Antibodies:
Go to our pre-filtered search.
Human Monoclonal GAA Primary Antibody for ELISA, WB - ABIN560974
Xiao, Westbroek, Motabar, Lea, Hu, Velayati, Zheng, Southall, Gustafson, Goldin, Sidransky, Liu, Simeonov, Tamargo, Ribes, Matalonga, Ferrer, Marugan: Discovery of a novel noniminosugar acid ? glucosidase chaperone series. in Journal of medicinal chemistry 2012
Show all 2 Pubmed References
GAA mutation is associated with Pompe disease.
Enzyme activities (acid alpha-glucosidase (GAA), galactocerebrosidase (GALC (show GALC Antibodies)), glucocerebrosidase (GBA (show GBA Antibodies)), alpha-galactosidase A (GLA (show GLA Antibodies)), alpha-iduronidase (IDUA (show IDUA Antibodies)) and sphingomyeline phosphodiesterase-1 (SMPD-1 (show SMPD1 Antibodies))) were measured on ~43,000 de-identified dried blood spot (DBS (show MCF2L Antibodies)) punches, and screen positive samples were submitted for DNA sequencing to obtain genotype confirmation of disease risk
enzyme replacement therapy (ERT (show ELF3 Antibodies)) (alglucosidase alfa) stabilizes respiratory function and improves mobility and muscle strength in late-onset Pompe disease.Lysosomal glycogen (show GYS1 Antibodies) in muscle biopsies from treatment-naive LOPD patients was reduced post-ERT (show ELF3 Antibodies) (alglucosidase alfa).
In adults with Pompe disease, antibody formation does not interfere with rhGAA efficacy in the majority of patients, is associated with IARs (show IARS Antibodies), and may be attenuated by the IVS1/delex18 GAA genotype
Reanalysis of the patient's DNA sample using next generation sequencing (NGS) of a panel of target genes causing glycogen (show GYS1 Antibodies) storage disorders demonstrated compound heterozygosity for a point mutation and an exonic deletion in the GAA gene.
Thirteen novel and two common GAA mutations were identified in this study. The allelic frequency of c.2662G > T (p.Glu888X) was 23.1% in northern Chinese patients and 4.2% in southern Chinese patients, whereas the allelic frequency of c.1935C >A (p.Asp645Glu) was 20.8% in southern and 3.8% in northern Chinese patients.
This is the first report of the alpha-glucosidase (show AGLU Antibodies) inhibitory activity of compounds 20, 26, and 29, and the findings support the important role of Eremanthus species as novel sources of new drugs and/or herbal remedies for treatment of type 2 diabetes.
Compared with controls, GAA gene expression levels in coronary artery disease (CAD (show CAD Antibodies)) patients were significantly increased, suggesting that GAA may be involved in the CAD (show CAD Antibodies) development.
Study reports on the clinical, biochemical, morphological, muscle imaging, and genetic findings of six adult Pompe patients from five unrelated families with the c.-32-13T>G GAA gene mutation in homozygous state. All patients had decreased GAA activity and elevated creatine kinase levels.
glycogen (show GYS1 Antibodies) storage disease type II is caused by deficiency of GAA activity resulting from mutation of GAA gene
the data unequivocally confirm that systemic absence of GAA induces a complex neuropathological cascade in the spinal cord.
GAA enzyme deficiency leads to glycogen (show GYS1 Antibodies) accumulation in the trachea and bronchi and impairs the ability of lower airway smooth muscle to regulate calcium and respond appropriately to bronchodilator or constrictors.
GAA deficiency results in reduced mTORC1 activation that is partly responsible for the skeletal muscle wasting phenotype and can be amerliorated by leucine supplementation.
Results describe the inhibitory effects of Chana series chalcone derivatives on the activities of alpha-glucosidase (show AGLU Antibodies) and DPP-4 (show DPP4 Antibodies), and on adipocyte differentiation.
Power and torque did not change with age in control animals, but declined significantly in acid 1-4 alpha-glucosidase (show AGLU Antibodies) knockout mice in three age groups.
These studies suggest that hyase enhances penetration of enzyme into the tissues including muscle during ERT (show ELF3 Antibodies) and therefore hyase pretreatment may be important in treating Pompe disease.
The lethal mutation 1057DeltaTA of GAA is present in the Droughtmaster breed, with pathology identical to that reported in pure Brahman animals.
This gene encodes acid alpha-glucosidase, which is essential for the degradation of glycogen to glucose in lysosomes. Different forms of acid alpha-glucosidase are obtained by proteolytic processing. Defects in this gene are the cause of glycogen storage disease II, also known as Pompe's disease, which is an autosomal recessive disorder with a broad clinical spectrum. Three transcript variants encoding the same protein have been found for this gene.
, aglucosidase alfa
, lysosomal alpha-glucosidase
, transmembrane and coiled-coil domains protein 1
, acid (Pompe disease, glycogen storage disease type II)
, acid alpha-glucosidase
, glucosidase, alpha; acid (Pompe disease, glycogen storage disease type II)